Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA4 | P48058 | 15/20 | 0.48 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.40 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.40 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.40 |
| ▸ | KIF11 | P52732 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | MMP1 | P03956 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | MMP3 | P08254 | 1/20 | 0.36 |
| ▸ | MMP7 | P09237 | 1/20 | 0.36 |
| ▸ | MMP9 | P14780 | 1/20 | 0.36 |
| ▸ | MMP13 | P45452 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13255710 | 1.00 | GRIA4 (0.48) | GRIA4GRIA1GRIA2GRIA3KIF11 | |
| SCHEMBL6561639 | 0.95 | GRIA4 (0.51) | GRIA4GRIA1CA1CA2 | |
| SCHEMBL5186189 | 0.94 | GRIA4 (0.54) | GRIA4GRIA1GRIA2GRIA3KIF11 | |
| SCHEMBL13663202 | 0.93 | GRIA4 (0.43) | GRIA4GRIA1GRIA2GRIA3KIF11 | |
| SCHEMBL6155981 | 0.90 | KIF11 (0.51) | GRIA4KIF11CA1CA2 | |
| SCHEMBL5186129 | 0.90 | GRIA4 (0.41) | GRIA4GRIA1GRIA2GRIA3KIF11 | |
| SCHEMBL6155942 | 0.90 | KIF11 (0.51) | GRIA4KIF11CA1CA2 | |
| SCHEMBL5186185 | 0.90 | GRIA4 (0.56) | GRIA4GRIA1GRIA2GRIA3KIF11 | |
| SCHEMBL5186014 | 0.90 | KIF11 (0.51) | GRIA4KIF11CA1CA2 | |
| SCHEMBL5186058 | 0.89 | GRIA4 (0.57) | GRIA4MMP1MMP2MMP3MMP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010087982-A1 | GLUR2 RECEPTOR MODULATORS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2010-08-05 | — | — | WO | disclosed |
| WO-2010087982-A1 | GLUR2 RECEPTOR MODULATORS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2010-08-05 | — | — | WO | disclosed |
| US-20090270508-A1 | GluR2 receptor modulators | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2009-10-29 | — | — | US | disclosed |
| US-20090270508-A1 | GluR2 receptor modulators | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270508-A1 | GluR2 receptor modulators | GRM2, GRIK2, GRIN2A | GRIA4 16/4885GRIA1 19/4885GRIA2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.